Evergreen Capital Management LLC Purchases New Shares in Moderna, Inc. (NASDAQ:MRNA)

Evergreen Capital Management LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 2,080 shares of the company’s stock, valued at approximately $247,000.

A number of other hedge funds also recently bought and sold shares of the company. Public Sector Pension Investment Board lifted its position in shares of Moderna by 66.8% in the 2nd quarter. Public Sector Pension Investment Board now owns 13,880 shares of the company’s stock valued at $1,648,000 after acquiring an additional 5,557 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Moderna in the second quarter valued at $75,000. Frank Rimerman Advisors LLC boosted its position in shares of Moderna by 349.6% in the second quarter. Frank Rimerman Advisors LLC now owns 3,152 shares of the company’s stock worth $374,000 after buying an additional 2,451 shares during the period. Profund Advisors LLC boosted its position in shares of Moderna by 20.9% in the second quarter. Profund Advisors LLC now owns 56,218 shares of the company’s stock worth $6,676,000 after buying an additional 9,719 shares during the period. Finally, Summit Trail Advisors LLC raised its position in Moderna by 12.8% during the second quarter. Summit Trail Advisors LLC now owns 3,558 shares of the company’s stock valued at $423,000 after buying an additional 403 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Stock Up 2.8 %

MRNA opened at $65.75 on Friday. The firm has a market cap of $25.20 billion, a P/E ratio of -4.20 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The business has a 50 day moving average price of $85.34 and a 200 day moving average price of $109.78. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the previous year, the company earned ($3.62) earnings per share. Moderna’s revenue for the quarter was down 29.9% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -9.86 EPS for the current year.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 15,000 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the completion of the sale, the president now owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the completion of the sale, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 78,158 shares of company stock worth $9,259,012. Company insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on MRNA. The Goldman Sachs Group decreased their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and lowered their price objective for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Bank of America cut their target price on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research report on Friday, September 13th. Leerink Partners lowered their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Finally, TD Cowen cut their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a report on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $100.44.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.